This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Array BioPharma CEO: Novartis Deal a Massive Momentum Builder

Array BioPharma shares have surged in the wake of the company's oncology deal with Novartis and the good news is expected to continue, said the company's CEO Ron Squarer. Squarer said he has high expectations following Array's agreement with Novartis in which the company regained full rights to a previously partnered Phase 3 oncology drug program (binimetinib), and acquired a second Phase 3 oncology program (encorafenib). In addition to an expected regulatory filing for binimetinib in the first half of 2016, Squarer anticipates filing for a uveal melanoma drug (selumetinib) in which it partnered with AstraZeneca.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.